Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) [Phase 1]

View source ↗

Summary

Phase 1 study of pembrolizumab in combination with dinaciclib in hematologic malignancies was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• Dinaciclib (dinaciclib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: rrCLL, rrMM | Phase 1 | Status: TERMINATED | Results posted: 2021-03-01